image_alt_text
8

Jennifer R. Cochran, Ph.D.

AIMBE College of Fellows Class of 2018
For fundamental advances in protein engineering, the development of tools for discovery, diagnosis and therapies, and for leadership in bioengineering.

Jennifer Cochran elected to the National Academy of Engineering

Via Stanford University | February 18, 2025

Jennifer Cochran and Christopher Manning have earned one of engineering’s highest professional distinctions.

Stanford faculty members Jennifer Cochran and Christopher Manning have been newly elected to the National Academy of Engineering (NAE). This honor is among the highest professional distinctions accorded engineers and recognizes accomplished experts from business, academia, and government.

“As a member of the National Academy of Engineering, these professionals belong to a select group of national and international peers who advance the welfare and prosperity of the nation by providing independent advice on matters involving engineering and technology, and by promoting a vibrant engineering profession and public appreciation of engineering,” said NAE President John L. Anderson… Continue reading.

New Synthetic Cancer Immunotherapy Effective in Mouse Study

Via Clinical OMICs | November 12, 2021

Stanford researchers have developed a new synthetic molecule, called PIP-CpG, that combines a tumor-targeting agent with a molecule that triggers immune activation. This treatment, can be administered intravenously and can make its way to multiple tumor sites, where it recruits immune cells against cancer.

Three doses of this new immunotherapy prolonged the survival of six of nine laboratory mice with an aggressive triple negative breast cancer. Of the six, three appeared cured of their cancer over the duration of the months long study. A single dose of this molecule induced complete tumor regression in five of ten mice. The synthetic molecule showed similar results in a mouse model of pancreatic cancer… Continue reading.

Protein decoy stymies lung cancer growth in mice, study finds

Via Medical Xpress | November 7, 2019

Scientists at Stanford and UC-San Francisco have developed an experimental drug that targets a currently untreatable type of lung cancer responsible for generating roughly 500,000 newly diagnosed cases worldwide each year.

A paper to be published online Nov. 7 in Nature Medicine reports that the researchers slowed the spread of this cancer in mice by neutralizing a single protein that would otherwise set off a chain reaction, causing runaway growth.

The paper is the result of a long-term collaboration between Stanford bioengineer Jennifer Cochran, Ph.D., and UCSF cancer researcher Alejandro Sweet-Cordero, MD… Continue reading.

Dr. Jennifer Cochran Inducted into Medical and Biological Engineering Elite

Via AIMBE | April 10, 2018

WASHINGTON, D.C.—The American Institute for Medical and Biological Engineering (AIMBE) has announced the induction of Jennifer R. Cochran, Ph.D., Professor and Shriram Chair of Bioengineering, Professor, by courtesy, of Chemical Engineering, Bioengineering, Stanford University, to its College of Fellows. Dr. Cochran was nominated, reviewed, and elected by peers and members of the College of Fellows for fundamental advances in protein engineering, the development of tools for discovery, diagnosis and therapies, and for leadership in bioengineering.